Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell Lymphoma Specialty Channel

Diffuse Large B-Cell Lymphoma
Specialty Channel
Quiz
Autologous Hematopoietic Cell Transplantation or CAR-T Therapy for Patients With Relapsed LBCL
09/30/2024
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to...
09/30/2024
Oncology
News
Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission
08/30/2024
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a...
08/30/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
News
Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
R-CHOP Followed by R-ICE Regimen vs Standard-of-Care Therapy for Patients With Non-GCB DLBCL
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
News
Lisocabtagene Maraleucel Shows Continued Efficacy, Manageable Safety for Patients with R/R LBCL
02/28/2024

Amber Denham

Amber Denham
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...
02/28/2024
Oncology
Quiz
Blinatumomab After ASCT as a Treatment Option Among Patients With Relapsed DLBCL
02/27/2024
02/27/2024
Oncology
News
Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
02/21/2024
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
News
Blinatumomab Consolidation After Auto-SCT Yields Safety, Tolerability Among Patients With Relapsed DLBCL
02/02/2024
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after...
02/02/2024
Oncology
Gilles Salles, MD, PhD
Videos
Examining Factors to Consider in the Treatment of Patients With Indolent B-Cell Lymphomas
01/15/2024
Gilles Salles, MD, PhD, offers advice for fellow oncologists in the B-cell lymphoma space, highlighting the need for strategically chosen therapies to minimize the risk of transformations.
Gilles Salles, MD, PhD, offers advice for fellow oncologists in the B-cell lymphoma space, highlighting the need for strategically chosen therapies to minimize the risk of transformations.
Gilles Salles, MD, PhD, offers...
01/15/2024
Oncology

News

News
Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission
08/30/2024
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a...
08/30/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology
News
Lisocabtagene Maraleucel Shows Continued Efficacy, Manageable Safety for Patients with R/R LBCL
02/28/2024

Amber Denham

Amber Denham
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...
02/28/2024
Oncology
News
Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
02/21/2024
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
News
Blinatumomab Consolidation After Auto-SCT Yields Safety, Tolerability Among Patients With Relapsed DLBCL
02/02/2024
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after...
02/02/2024
Oncology
News
Rituximab Plus Lenalidomide Treatment Shows Promise for Older Patients with DLBCL
01/11/2024
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and...
01/11/2024
Oncology
News
Controlling Nutritional Status Score Shows Prognostic Value Among Older Patients With DLBCL
01/03/2024
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in...
01/03/2024
Oncology
News
CD5 Biomarker Effective for Identifying DLBCL Subtypes Sensitive to BTK Inhibitor Therapy
01/03/2024
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature...
01/03/2024
Oncology
Conference Coverage
R-CHOP Plus Tazemetostat Therapy Feasible Among Older Patients With Newly Diagnosed DLBCL
12/11/2023
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2...
12/11/2023
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Interactive Features

Quiz
Autologous Hematopoietic Cell Transplantation or CAR-T Therapy for Patients With Relapsed LBCL
09/30/2024
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to results from a retrospective observational study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation fails to...
True or False: According to...
09/30/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
Quiz
Blinatumomab After ASCT as a Treatment Option Among Patients With Relapsed DLBCL
02/27/2024
02/27/2024
Oncology
Quiz
Treating DLBCL With Tafasitamab Plus R-CHOP, With or Without Lenalidomide
12/15/2023
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to findings from the phase 1b First-MIND study, tafasitamab plus the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen with or without the addition of lenalidomide demonstrated...
True or False: According to...
12/15/2023
Oncology
Quiz
Acalabrutinib Plus Danvatirsen for R/R DLBCL
12/05/2023
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of the phase 1 PRISM trial, which investigated the use of BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen among patients with R/R DLBCL?
What were the key findings of...
12/05/2023
Oncology
Quiz
Standard vs 4-Cycle Regimen of R-CHOP for Non-Bulky, Low-Risk DLBCL
11/07/2023
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a phase 3 trial, how did a 4-cycle regimen of R-CHOP compare to the standard regimen in treating patients with non-bulky, low-risk DLBCL?
According to findings from a...
11/07/2023
Oncology
Quiz
Simplified CIRS-Derived Comorbidity Index For DLBCL Patients Indicated for CAR T-Cell Therapy
10/18/2023
True or False: A simplified cumulative illness rating scale (CIRS)-derived comorbidity index was able to assess and predict adverse outcomes among patients with R/R DLBCL indicated for chimeric antigen receptor T-cell (CAR T) therapy.
True or False: A simplified cumulative illness rating scale (CIRS)-derived comorbidity index was able to assess and predict adverse outcomes among patients with R/R DLBCL indicated for chimeric antigen receptor T-cell (CAR T) therapy.
True or False: A simplified...
10/18/2023
Oncology
Quiz
Treating R/R DLBCL With Mosunetuzumab
10/03/2023
True or False: Mosunetuzumab demonstrated high efficacy and manageable safety among patients with R/R DLBCL, including those previously treated with CAR T-cell therapy.
True or False: Mosunetuzumab demonstrated high efficacy and manageable safety among patients with R/R DLBCL, including those previously treated with CAR T-cell therapy.
True or False: Mosunetuzumab...
10/03/2023
Oncology
Quiz
BET Inhibitor Trotabresib for Heavily-Pretreated R/R DLBCL
09/11/2023
True or False: Findings from a phase 1 trial indicated that BET protein inhibitor trotabresib monotherapy demonstrated potential, and antitumor activity, among patients with heavily pretreated relapsed/refractory DLBCL, as well as patients...
True or False: Findings from a phase 1 trial indicated that BET protein inhibitor trotabresib monotherapy demonstrated potential, and antitumor activity, among patients with heavily pretreated relapsed/refractory DLBCL, as well as patients...
True or False: Findings from a...
09/11/2023
Oncology
Quiz
High-Dose Chemotherapy and Auto-HSCT in First Remission for Intermediate/High-Risk Stage IV DLBCL
09/05/2023
True or False: High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem-cell transplantation (auto-HSCT) in the first remission yielded effective results and improved prognosis among patients with intermediate/high-risk stage...
True or False: High-dose chemotherapy (HDCT) followed by autologous hematopoietic stem-cell transplantation (auto-HSCT) in the first remission yielded effective results and improved prognosis among patients with intermediate/high-risk stage...
True or False: High-dose...
09/05/2023
Oncology
Quiz
Adjuvant Pembrolizumab Plus Chemotherapy for Patients With Newly Diagnosed, High-Risk Endometrial Cancer
11/12/2024
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase...
11/12/2024
Oncology
Quiz
Using the PREMM5 Model to Detect Mutations Associated With Lynch Syndrome
11/06/2024
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene...
11/06/2024
Oncology
Quiz
Use of Luspatercept for Patients With Myelofibrosis-Associated Anemia
10/16/2024
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to...
10/16/2024
Oncology
Quiz
Comparing Custom Targeted DNA Sequencing Panel vs FISH for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL
10/15/2024
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to...
10/15/2024
Oncology
Quiz
Low-Dose Subcutaneous Decitabine Treatment for Patients With MF
10/11/2024
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to...
10/11/2024
Oncology
Quiz
Ibrutinib Plus Venetoclax for Patients With TP53-Mutated MCL
10/11/2024
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented...
10/11/2024
Oncology
Quiz
Long-Term Results of Acalabrutinib-Based Regimens in CLL
10/11/2024
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to...
10/11/2024
Oncology
Quiz
Use of Pirtobrutinib Among Patients With B-Cell Malignancies With Richter Transformation
10/08/2024
True or False: According to an analysis of the Richter transformation subgroup from the phase 1/2 BRUIN study, pirtobrutinib demonstrates encouraging safety and activity among patients with relapsed/refractory B-cell malignancies with Richter...
True or False: According to an analysis of the Richter transformation subgroup from the phase 1/2 BRUIN study, pirtobrutinib demonstrates encouraging safety and activity among patients with relapsed/refractory B-cell malignancies with Richter...
True or False: According to an...
10/08/2024
Oncology
Quiz
SHR-A1811 for HER2-Expressing Advanced Solid Tumors
10/03/2024
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811...
10/03/2024
Oncology
Quiz
Odronextamab Treatment for Patients With Heavily Pretreated R/R Follicular Lymphoma
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology

Recent News

News
Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission
08/30/2024
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a...
08/30/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology
News
Lisocabtagene Maraleucel Shows Continued Efficacy, Manageable Safety for Patients with R/R LBCL
02/28/2024

Amber Denham

Amber Denham
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...
02/28/2024
Oncology
News
Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
02/21/2024
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
News
Blinatumomab Consolidation After Auto-SCT Yields Safety, Tolerability Among Patients With Relapsed DLBCL
02/02/2024
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after...
02/02/2024
Oncology
News
Rituximab Plus Lenalidomide Treatment Shows Promise for Older Patients with DLBCL
01/11/2024
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and...
01/11/2024
Oncology
News
Controlling Nutritional Status Score Shows Prognostic Value Among Older Patients With DLBCL
01/03/2024
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in...
01/03/2024
Oncology
News
CD5 Biomarker Effective for Identifying DLBCL Subtypes Sensitive to BTK Inhibitor Therapy
01/03/2024
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature...
01/03/2024
Oncology
Conference Coverage
R-CHOP Plus Tazemetostat Therapy Feasible Among Older Patients With Newly Diagnosed DLBCL
12/11/2023
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2...
12/11/2023
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use